Last week, 23andMe reported dismal third-quarter fiscal results, tanking stocks in the company.
This year, the partnership became non-exclusive, which means 23andMe can strike deals with more pharmaceutical companies to milk more money out of its DNA trove.
[
add
]
[
|
|
...
]